• 대한한의학회지
• /
• 제41권3호
• /
• pp.162-172
• /
• 2020

Objectives: The purpose of study was to report the clinical improvement of Chronic Obstructive Pulmonary Disease (COPD) patients treated with Korean medicine pulmonary rehabilitation. Methods: The patients were treated with Lung-conduction exercise, Chuna manual therapy, Exercise therapy. To assess the treatment outcomes, we used the pulmonary function test (PFT), modified medical research council scale (mMRC), 6-minute walk distance (6MWD), peak expiratory flow rate (PEFR), COPD assessment test (CAT), St. George respiratory questionnaire (SGRQ). Results: After treatments, the patient's clinical symptoms were improved with CAT, SGRQ's significant decrease and PFT, mMRC, 6MWD and PEFR were maintained or improved slightly. Conclusions: The Korean medicine pulmonary rehabilitation was effective in the treatment of COPD patients. This study suggested the possibility of Korean Medicine pulmonary rehabilitation program in the clinic.

• 한국임상약학회지
• /
• 제26권4호
• /
• pp.298-305
• /
• 2016

Background: This study is to investigate the prescription patterns and factors related to the number of medications treating chronic obstructive pulmonary disease (COPD) in patients under 65 years old according to GOLD guidelines. Methods: We retrospectively analyzed the medical records of patients aged 40-64 years with a diagnosis of COPD from January to March 2016. Patients were classified by combined assessment of COPD (grades A, B, C, D) using spirometry, exacerbation history, mMRC, and/or CAT results. We analyzed prescribed medications, treatment options and factors related to the numbers of COPD medications. Results: The total number of prescriptions were 251. About 35.5% of patients were classified as GOLD A, 34.2% as GOLD B, 17.1% as GOLD C and 13.2% as GOLD D. Inhaled bronchodilator was prescribed for 86.9% of patients and the most frequent COPD medication was long-acting muscarinic antagonist (LAMA) followed by inhaled corticosteroids/long acting beta agonist (ICS/LABA). The majority of low risk patients (GOLD A/B) were prescribed a monotherapy with LAMA or LABA. For high risk patients (GOLD C/D), combination treatment with ICS+LAMA+LABA was mostly prescribed. The 21.2% of patients in GOLD D received systemic corticosteroid. The average number of medications per prescription was 3.7, and this number increased with increasing COPD grade, COPD duration and lung function reduction ($FEV_1$, $FEV_1/FVC$). Conclusion: Generally high adherence to GOLD guideline recommendations was reported. Given the progressive nature of the disease, results suggest that closer attention to respiratory symptoms for early detection, diagnosis, and appropriate treatment of COPD is warranted.

• Tuberculosis and Respiratory Diseases
• /
• 제82권4호
• /
• pp.335-340
• /
• 2019

Background: Snoring is the cardinal symptom of obstructive sleep apnea (OSA). Snoring and upper airway obstruction associated with major oxygen desaturation may occur in populations undergoing flexible bronchoscopy. Methods: To evaluate the prevalence of patients at a high risk of having OSA among patients undergoing bronchoscopy with sedation and to investigate whether snoring during the procedure predicts patients who are at risk of OSA, we prospectively enrolled 517 consecutive patients who underwent the procedure with moderate sedation. Patients exhibiting audible snoring for any duration during the procedure were considered snorers. The STOP-Bang (Snoring, Tiredness, Observed apnea, high blood Pressure-Body mass index, Age, Neck circumference and Gender) questionnaire was used to identify patients at high (score ${\geq}3$ out of 8) or low risk (score <3) of OSA. Results: Of the 517 patients, 165 (31.9%) snored during bronchoscopy under sedation. The prevalence of a STOP-Bang score ${\geq}3$ was 61.9% (320/517), whereas 200 of the 352 nonsnorers (56.8%) and 120 of the 165 snorers (72.7%) had a STOP-Bang score ${\geq}3$ (p=0.001). In multivariable analysis, snoring during bronchoscopy was significantly associated with a STOP-Bang score ${\geq}3$ after adjustment for the presence of diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease, and stroke (adjusted odds ratio, 1.91; 95% confidence interval, 1.26-2.89; p=0.002). Conclusion: Two-thirds of patients undergoing bronchoscopy with moderate sedation were at risk of OSA based on the screening questionnaire. Snoring during bronchoscopy was highly predictive of patients at high risk of OSA.

• Tuberculosis and Respiratory Diseases
• /
• 제61권6호
• /
• pp.533-546
• /
• 2006

배 경: 만성폐쇄성폐질환의 여러 가지 호흡재활프로그램 중에서 자기효능감을 증진시키는 것이 호흡재활치료에 효과적이라는 국외 보고는 있으나 국내에서는 연구가 시도되지 않았다. 저자들은 만성폐쇄성폐질환자에서 자기효능감증진 호흡재활프로그램의 효과를 알아보기 위하여 이 연구를 하였다. 대상 및 방법: 대상은 호흡기내과 외래에서 진료 받는 만성폐쇄성폐질환자 중 GOLD분류에 의한 II,III 병기 환자로 하였으며, 치료군 18명, 대조군 18명으로 선정, 비교하였다. 연구는 무작위할당 대조군 전-후연구로 이루어졌다. 저자들이 개발한 자기효능감증진 호흡재활프로그램을 8주 동안 실시하였으며 치료군은 실시 전, 4주, 8주째는 1:1의 교육과 상담이 이루어졌고 전화상담은 매주 1~2회 이루어졌다. 교육과 상담으로 대리경험, 성취경험 등이 이루어지도록 하였고 매일 가정에서 운동훈련과 이완요법을 수행하도록 하여 성취경험과 정서적 이완이 이루어지도록 하였다. 대조군은 프로그램 실시 전에 1:1의 교육과 상담만 제공하였다. 평가는 자기효능감, 평소 호흡곤란, 운동유발호흡곤란, 운동내구성은 6분 걷기 거리로, 폐기능, 삶의 질 등을 양 군에서 측정 비교하였다. 결 과: 자기효능감증진 호흡재활프로그램은 대조군보다 치료군에서 유의하게 자기효능감이 향상되었다. 평상 시 호흡곤란, 운동 시 호흡곤란, 6분 걷기 거리도 치료군에서 유의하게 향상되었다. 그러나 폐기능은 유의한 차이가 없었다. 자기효능감증진 호흡재활프로그램은 치료군에서 삶의 질도 유의하게 향상되었다.. 결 론: 만성폐쇄성폐질환자에서 자기효능감증진 호흡재활프로그램은 자기효능감, 운동내구성, 삶의 질을 증가시키고 운동유발 호흡곤란 정도를 감소시키는 효과가 있었으며, 자기효능감증진 호흡재활프로그램은 만성폐쇄성폐질환자의 호흡재활치료로 효과적으로 활용될 수 있겠다.

• Tuberculosis and Respiratory Diseases
• /
• 제59권3호
• /
• pp.242-249
• /
• 2005

• 대한간호학회지
• /
• 제33권1호
• /
• pp.87-94
• /
• 2003

Purpose: The purpose of this study was to identify the factors influencing Symptoms of Stress in patients with chronic illness. Method: Data were collected by questionnaires from 1,748 patients with chronic disease in General Hospital in Seoul. Chronic diseases of were cardiac disease including hypertension, peptic ulcer, pulmonary disease included COPD and asthma, DM, and chronic kidney disease. The data were analyzed using descriptive statistics, pearson correlation coefficients, and stepwise multiple regression. Result: 1. The level of symptoms of stress was moderate(M=2.17). 2. The score of symptoms of stress showed significantly positive correlation with the score of mood state(r=.58, p=.00), perceived stress(r=.57, p=.00), and ways of coping(r=.33, p=.00). The symptoms of stress showed significantly negative correlation with the score of social support(r=-.37, p=.00) and self-esteem(r=-.19, p=.00). 3. The most powerful predictor of symptoms of stress was mood state and the variance explained was 34%. A combination of mood state, ways of coping, perceived stress, social support, and duration of illness account for 45% of the variance in symptoms of stress of the patients with chronic illness. Conclusion: This study suggest that mood state, ways of coping, perceived stress, and social support are significantly influencing factors on symptoms of stress of the patients with chronic illness.

• Tuberculosis and Respiratory Diseases
• /
• 제86권4호
• /
• pp.272-283
• /
• 2023

Background: In patients with chronic obstructive pulmonary disease (COPD), decreased muscle mass is a frequently encountered comorbidity in clinical practice. However, the evaluation of muscle mass in patients with COPD in real-world practice is rare. Methods: We retrospectively reviewed the electronic medical records of all patients with COPD who underwent bioelectrical impedance analysis at least once between January 2011 and December 2021 in three hospitals. Then, we analyzed the performance rate of muscle mass measurement in the patients and the correlation between muscle mass, clinical parameters, and COPD prognosis. Results: Among the 24,502 patients with COPD, only 270 (1.1%) underwent muscle mass measurements. The total skeletal muscle mass index was significantly correlated with albumin, alanine transaminase, and creatinine to cystatin C ratio in patients with COPD (r=0.1614, p=0.011; r=0.2112, p=0.001; and r=0.3671, p=0.001, respectively). Acute exacerbation of COPD (AE COPD) was significantly correlated with muscle mass, especially the truncal skeletal muscle mass index (TSMI) in males (r=-0.196, p=0.007). In the multivariate analysis, TSMI and cystatin C were significant risk factors for AE COPD (hazard ratio, 0.200 [95% confidence interval, CI, 0.048 to 0.838] and 4.990 [95% CI, 1.070 to 23.278], respectively). Conclusion: Low muscle mass negatively affects the clinical outcomes in patients with COPD. Despite its clinical significance, muscle mass measurement is performed in a small proportion of patients with COPD. Therefore, protocols and guidelines for the screening of sarcopenia in patients with COPD should be established.

• Tuberculosis and Respiratory Diseases
• /
• 제87권2호
• /
• pp.155-164
• /
• 2024

Background: Exercise capacity is associated with lung function decline in chronic obstructive pulmonary disease (COPD) patients, but a discrepancy between exercise capacity and airflow limitation exists. This study aimed to explore factors contributing to this discrepancy in COPD patients. Methods: Data for this prospective study were obtained from the Korean COPD Subgroup Study. The exercise capacity and airflow limitation were assessed using the 6-minute walk distance (6-MWD; m) and forced expiratory volume in 1 second (FEV₁). Participants were divided into four groups: FEV₁ >50%+6-MWD >350, FEV₁ >50%+6-MWD ≤350, FEV₁ ≤50%+6-MWD >350, and FEV₁ ≤50%+6-MWD ≤350 and their clinical characteristics were compared. Results: A total of 883 patients (male:female, 822:61; mean age, 68.3±7.97 years) were enrolled. Among 591 patients with FEV₁ >50%, 242 were in the 6-MWD ≤350 group, and among 292 patients with FEV₁ ≤50%, 185 were in the 6-MWD >350 group. The multiple regression analyses revealed that male sex (odds ratio [OR], 8.779; 95% confidence interval [CI], 1.539 to 50.087; p=0.014), current smoking status (OR, 0.355; 95% CI, 0.178 to 0.709; p=0.003), and hemoglobin levels (OR, 1.332; 95% CI, 1.077 to 1.648; p=0.008) were significantly associated with discrepancies in exercise capacity and airflow limitation in patients with FEV₁ >50%. Meanwhile, in patients with FEV₁ ≤50%, diffusion capacity of carbon monoxide (OR, 0.945; 95% CI, 0.912 to 0.979; p=0.002) was significantly associated with discrepancies between exercise capacity and airflow limitation. Conclusion: The exercise capacity of COPD patients may be influenced by factors other than airflow limitation, so these aspects should be considered when assessing and treating patients.

• Tuberculosis and Respiratory Diseases
• /
• 제46권2호
• /
• pp.204-214
• /
• 1999

연구배경: 만성폐질환자가 일상생활에서 느끼는 호흡곤란정도, 안정상태에서 시행된 폐기능검사 및 심폐운동검사사이에 어떤 관계가 있는지, 안정시 폐기능검사와 심폐운동검사가 호흡곤란의 정도를 잘 반영하는지 등을 연구하고자 만성폐질환자에서 기초호흡곤란지수, 안정시 폐기능검사 및 심폐운동능력을 조사하여 다음과 같은 결과를 얻었다. 연구방법: 최근 2개월내에 악화되지 않은 만성폐질환자 50명을, 기존의 안정시 폐기능검사 및 증상 제한적 심폐운동검사결과를 이용하는 폐기능손상/장애 평가기준과 baseline dyspnea index의 초점점수에 따라 저자들이 임의로 정한 기준으로 비중증군과 중증군으로 분류후 각 군간의 안정시 폐기능검사, 심폐운동검사, 초점점수를 비교하였으며, 각 기준의 상호 민감도 및 특이도를 비교하였다. 연구결과: 안정시 폐기능검사치상 중증군에서 max WR(%), $VO_2$max, $VO_2$max(%) 및 초점 점수가 유의하게 낮았고(p<0.01), $VO_2$max으로 구분하였을 때는 중증군에서 안정시 폐기능검사치 중 $FEV_1$(%)만 유의하게 낮았다(p<0.05). Max WR, max WR(%) 및 초점 접수는 중증군에서 유의하게 낮았다(p<0.01) $VO_2$max(%)이 60% 미만인 경우를 중증군으로 하였을 때 $FEV_1$, $FEV_1$(%), MVV(%), max WR와 max WR(%), 초점 점수 등이 중증군에서 유의하게 낮았다(p<0.05). 초점 점수의 중위수 혹은 5점보다 낮은 경우를 중증군으로 분류하였을 때, 중증군에서 안정시 폐기능치들은 비중증군과 차이가 없었으나(p>0.05), max WR와 max WR(%), $VO_2$max와 $VO_2$max(%)는 유의하게 낮았다(p<0.01). 초점점수와 $VO_2$max의 상관계수는 0.51(p<0.01), $VO_2$max(%)은 0.52(p<0.01)이었으며, 안정시 폐기능 검사치 중 $FEV_1$(%)은 0.41(p<0.01)였다. 초점 점수의 $VO_2$max에 대한 결정계수는 0.26(p=0.0002)였고, $VO_2$max(%)에 대한 결정계수는 0.06(p=0.0001)였다. $FEV_1$은 각각 0.08(p=0.01), 0.38(p=0.0189)였다. 안정시 폐기능검사치 $VO_2$max, $VO_2$max(%)를 기준으로 중증 폐기능손상을 구분하였을 때 선택기준에 따라 민감도와 특이도가 차이가 있었고, 초점 점수의 중위수 및 5점을 기준으로 중증 폐기능 손상을 분류했을 때의 민감도 및 특이도와 큰 차이가 없었다. 결 론: 이상과 같은 결과로 안정시 폐기능검사만으로는 $VO_2$max를 정확하게 예측하기 힘들며, 특별한 금기사항이 없는 한 안정시 폐기능검사상 정상 혹은 경미한 손상을 보이는 환자뿐만 아니라 중증손상을 보이는 환자에서도 심폐운동검사를 시행하여 폐기능 손상 평가의 정확도를 높이는 것이 좋을 것으로 여겨지며, 폐기능 손상평가의 기존 기준들에 호흡곤란정도를 반영할 수 있을 것으로 여겨진다.

• Tuberculosis and Respiratory Diseases
• /
• 제81권4호
• /
• pp.281-288
• /
• 2018

Background: There are limited number of studies that investigate clinical variables instead of chronic obstructive lung disease (COPD) management according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 classification. The aim of the study was to investigate whether there was a difference between GOLD 2017 classification and spirometric stage in clinical variables in patients with COPD. The data of 427 male patients with stable COPD were investigated retrospectively. Methods: Patients were allocated into combined assessment of GOLD 2017 and spirometric stage. Age, amount of smoking, pulmonary function, modified Medical Research Council (mMRC), incremental shuttle walk test (ISWT), Hospital Anxiety-Depression Scale (HADS), St. George's Respiratory Questionnaire (SGRQ), body mass index (BMI), and fat free mass index (FFMI) were recorded. Results: Seventy-three (17%) patients were in group A, 103 (24%) constituted group B, 38 (9%) were included in group C, and 213 (50%) comprised group D according to the combined assessment of GOLD 2017. Twenty-three patients (5%) were in stage 1, 95 (22%) were in stage 2, 149 (35%) were in stage 3, and 160 (38%) were in stage 4 according to spirometric stage. According to GOLD 2017, age, amount of smoking, mMRC, BMI, FFMI, SGRQ, HADS, forced vital capacity, forced expiratory volume in 1 second ($FEV_1$), and ISWT were significantly different between groups. Ages, amount of smoking, FFMI, BMI, HADS of group A were different from B and D. Smiliar values of $FEV_1$ were found in A-C and B-D. A and C had smiliar ISWT. According to spirometric stage, BMI, FFMI of stage 4 were statistically different. mMRC, ISWT, and SGRQ of stages 3 and 4 were different from other stages, amongst themselves. $FEV_1$ was correlated with mMRC, SGRQ, anxiety scores, BMI, FFMI, and ISWT. Conclusion: This study showed that the GOLD ABCD classification might not represent the severity of COPD sufficiently well in terms of lung function or exercise capacity. The combination of both spirometric stage and combined assessment of GOLD 2017 is important, especially for estimating clinical variables.